According to Reuters, two pharmaceutical companies were fined by China’s market regulator for engaging in monopolistic behavior.
Grand Pharmaceutical was fined 136 million yuan ($19.68 million) and had 149 million yuan of “illegal revenue” confiscated for engaging in a monopolistic agreement with Wuhan Healthcare Pharmaceuticals.
Related: UK: CMA accuses pharma firms of market allocation
Wuhan Healcare Pharmaceuticals was fined 4.13 million yuan by the regulator and had slightly over 30 million yuan of its revenue confiscated.
In recent months, Chinese regulatory authorities have initiated antitrust investigations on various sectors, with a particular focus on technology corporations, including Alibaba Group.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI